Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free UG Stock Alerts

United-Guardian (UG) Competitors

United-Guardian logo
$7.14 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern
Compare

UG vs. VTVT, VANI, RFL, PLYX, and PYPD

Should you buy United-Guardian stock or one of its competitors? United-Guardian's main competitors and comparable companies include vTv Therapeutics (VTVT), Vivani Medical (VANI), Rafael (RFL), Polaryx Therapeutics (PLYX), and PolyPid (PYPD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does United-Guardian compare to vTv Therapeutics?

United-Guardian (NASDAQ:UG) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

23.2% of United-Guardian shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 29.0% of United-Guardian shares are held by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

United-Guardian has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market.

United-Guardian has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United-Guardian$10.55M3.11$2.11M$0.5413.22
vTv Therapeutics$1.02M128.82-$26.97M-$1.06N/A

United-Guardian has a net margin of 22.01% compared to vTv Therapeutics' net margin of 0.00%. United-Guardian's return on equity of 22.24% beat vTv Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
United-Guardian22.01% 22.24% 19.12%
vTv Therapeutics N/A -6.27%-5.06%

In the previous week, vTv Therapeutics had 5 more articles in the media than United-Guardian. MarketBeat recorded 5 mentions for vTv Therapeutics and 0 mentions for United-Guardian. vTv Therapeutics' average media sentiment score of 0.67 beat United-Guardian's score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
United-Guardian Neutral
vTv Therapeutics Positive

vTv Therapeutics has a consensus target price of $55.83, suggesting a potential upside of 67.42%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe vTv Therapeutics is more favorable than United-Guardian.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
United-Guardian
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
vTv Therapeutics
2 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.67

Summary

United-Guardian beats vTv Therapeutics on 10 of the 17 factors compared between the two stocks.

How does United-Guardian compare to Vivani Medical?

Vivani Medical (NASDAQ:VANI) and United-Guardian (NASDAQ:UG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Vivani Medical presently has a consensus target price of $3.75, indicating a potential upside of 151.68%. Given Vivani Medical's stronger consensus rating and higher possible upside, equities analysts clearly believe Vivani Medical is more favorable than United-Guardian.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vivani Medical
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
United-Guardian
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Vivani Medical had 2 more articles in the media than United-Guardian. MarketBeat recorded 2 mentions for Vivani Medical and 0 mentions for United-Guardian. Vivani Medical's average media sentiment score of 0.96 beat United-Guardian's score of 0.00 indicating that Vivani Medical is being referred to more favorably in the media.

Company Overall Sentiment
Vivani Medical Positive
United-Guardian Neutral

6.8% of Vivani Medical shares are owned by institutional investors. Comparatively, 23.2% of United-Guardian shares are owned by institutional investors. 53.3% of Vivani Medical shares are owned by insiders. Comparatively, 29.0% of United-Guardian shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

United-Guardian has higher revenue and earnings than Vivani Medical. Vivani Medical is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vivani MedicalN/AN/A-$26.61M-$0.35N/A
United-Guardian$10.55M3.11$2.11M$0.5413.22

Vivani Medical has a beta of 2.36, indicating that its share price is 136% more volatile than the broader market. Comparatively, United-Guardian has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

United-Guardian has a net margin of 22.01% compared to Vivani Medical's net margin of 0.00%. United-Guardian's return on equity of 22.24% beat Vivani Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Vivani MedicalN/A -191.05% -70.91%
United-Guardian 22.01%22.24%19.12%

Summary

United-Guardian beats Vivani Medical on 8 of the 15 factors compared between the two stocks.

How does United-Guardian compare to Rafael?

United-Guardian (NASDAQ:UG) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

23.2% of United-Guardian shares are owned by institutional investors. Comparatively, 11.3% of Rafael shares are owned by institutional investors. 29.0% of United-Guardian shares are owned by company insiders. Comparatively, 32.9% of Rafael shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

United-Guardian has higher revenue and earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United-Guardian$10.55M3.11$2.11M$0.5413.22
Rafael$920K146.96-$30.52M-$0.68N/A

United-Guardian has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Rafael has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

United-Guardian has a net margin of 22.01% compared to Rafael's net margin of -3,321.74%. United-Guardian's return on equity of 22.24% beat Rafael's return on equity.

Company Net Margins Return on Equity Return on Assets
United-Guardian22.01% 22.24% 19.12%
Rafael -3,321.74%-41.27%-35.32%

In the previous week, United-Guardian's average media sentiment score of 0.00 equaled Rafael'saverage media sentiment score.

Company Overall Sentiment
United-Guardian Neutral
Rafael Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
United-Guardian
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Rafael
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

United-Guardian beats Rafael on 10 of the 12 factors compared between the two stocks.

How does United-Guardian compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and United-Guardian (NASDAQ:UG) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

United-Guardian has a net margin of 22.01% compared to Polaryx Therapeutics' net margin of 0.00%. United-Guardian's return on equity of 22.24% beat Polaryx Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Polaryx TherapeuticsN/A N/A N/A
United-Guardian 22.01%22.24%19.12%

Polaryx Therapeutics presently has a consensus price target of $7.67, suggesting a potential upside of 283.33%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Polaryx Therapeutics is more favorable than United-Guardian.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polaryx Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
United-Guardian
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Polaryx Therapeutics had 5 more articles in the media than United-Guardian. MarketBeat recorded 5 mentions for Polaryx Therapeutics and 0 mentions for United-Guardian. Polaryx Therapeutics' average media sentiment score of 0.36 beat United-Guardian's score of 0.00 indicating that Polaryx Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Polaryx Therapeutics Neutral
United-Guardian Neutral

23.2% of United-Guardian shares are held by institutional investors. 45.8% of Polaryx Therapeutics shares are held by insiders. Comparatively, 29.0% of United-Guardian shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

United-Guardian has higher revenue and earnings than Polaryx Therapeutics. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Polaryx TherapeuticsN/AN/A-$8.98M-$0.08N/A
United-Guardian$10.55M3.11$2.11M$0.5413.22

Summary

United-Guardian beats Polaryx Therapeutics on 8 of the 15 factors compared between the two stocks.

How does United-Guardian compare to PolyPid?

United-Guardian (NASDAQ:UG) and PolyPid (NASDAQ:PYPD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

United-Guardian has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, PolyPid has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

United-Guardian has a net margin of 22.01% compared to PolyPid's net margin of 0.00%. United-Guardian's return on equity of 22.24% beat PolyPid's return on equity.

Company Net Margins Return on Equity Return on Assets
United-Guardian22.01% 22.24% 19.12%
PolyPid N/A -311.08%-150.83%

In the previous week, United-Guardian's average media sentiment score of 0.00 equaled PolyPid'saverage media sentiment score.

Company Overall Sentiment
United-Guardian Neutral
PolyPid Neutral

23.2% of United-Guardian shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 29.0% of United-Guardian shares are held by company insiders. Comparatively, 24.7% of PolyPid shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

United-Guardian has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United-Guardian$10.55M3.11$2.11M$0.5413.22
PolyPidN/AN/A-$34.17M-$1.48N/A

PolyPid has a consensus price target of $11.33, suggesting a potential upside of 110.27%. Given PolyPid's stronger consensus rating and higher possible upside, analysts clearly believe PolyPid is more favorable than United-Guardian.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
United-Guardian
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
PolyPid
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

United-Guardian beats PolyPid on 8 of the 13 factors compared between the two stocks.

Get United-Guardian News Delivered to You Automatically

Sign up to receive the latest news and ratings for UG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UG vs. The Competition

Export
MetricUnited-GuardianPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$32.78M$12.24B$7.25B$12.91B
Dividend Yield8.41%2.59%2.54%9.13%
P/E Ratio13.22792.20273.2725.43
Price / Sales3.11756.07624.5595.06
Price / Cash14.8115.1828.9235.62
Price / Book2.9311.0911.016.39
Net Income$2.11M$2.83B$3.49B$358.69M
7 Day Performance-1.38%4.42%1.63%0.22%
1 Month Performance-2.06%6.88%4.42%-0.10%
1 Year Performance-16.10%10.00%24.21%14.04%

United-Guardian Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UG
United-Guardian
1.2363 of 5 stars		$7.14
flat		N/A-16.1%$32.78M$10.55M13.2220
VTVT
vTv Therapeutics
2.9113 of 5 stars		$33.92
+0.0%		$55.83
+64.6%		+82.1%$133.65M$1.02MN/A9
VANI
Vivani Medical
3.3699 of 5 stars		$1.40
-1.4%		$3.75
+167.9%		+15.5%$126.28MN/AN/A20
RFL
Rafael
0.1873 of 5 stars		$2.30
+2.5%		N/A+79.3%$119.34M$920KN/A20
PLYX
Polaryx Therapeutics
3.0191 of 5 stars		$1.99
flat		$7.67
+285.3%		N/A$99.20MN/AN/A11

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:UG) was last updated on 9/7/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel